Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 936307, 7 pages
http://dx.doi.org/10.1155/2015/936307
Clinical Study

Zoledronic Acid May Reduce Intraoperative Bleeding in Spinal Tumors: A Prospective Cohort Study

1Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China
2Department of Orthopedics, Chengdu Military General Hospital, Chengdu 610083, China
3Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
4Department of Science and Training, Chengdu Military General Hospital, Chengdu 610083, China
5Department of Training, Second Military Medical University, Shanghai 200433, China

Received 11 August 2014; Accepted 11 October 2014

Academic Editor: Kuo-Sheng Hung

Copyright © 2015 Juan Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. Licata, “Discovery, clinical development, and therapeutic uses of bisphosphonates,” Annals of Pharmacotherapy, vol. 39, no. 4, pp. 668–677, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Costa and P. P. Major, “Effect of bisphosphonates on pain and quality of life in patients with bone metastases,” Nature Clinical Practice Oncology, vol. 6, no. 3, pp. 163–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. J. Morgan, J. A. Child, W. M. Gregory et al., “Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 8, pp. 743–752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Lacerna and J. Hohneker, “Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors,” Seminars in Oncology, vol. 30, no. 5, supplement 16, pp. 150–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Dhillon and K. A. Lyseng-Williamson, “Zoledronic acid: a review of its use in the management of bone metastases of malignancy,” Drugs, vol. 68, no. 4, pp. 507–534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Boriani, J. N. Weinstein, and R. Biagini, “Spine update primary bone tumors of the spine: terminology and surgical staging,” Spine, vol. 22, no. 9, pp. 1036–1044, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. H. L. Frankel, “Ascending cord lesion in the early stages following spinal injury,” Paraplegia, vol. 7, no. 2, pp. 111–118, 1969. View at Google Scholar · View at Scopus
  8. A. Edler, D. J. Murray, and R. B. Forbes, “Blood loss during posterior spinal fusion surgery in patients with neuromuscular disease: is there an increased risk?” Paediatric Anaesthesia, vol. 13, no. 9, pp. 818–822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Wu, W. Zheng, J.-R. Xiao, X. Sun, W.-Z. Liu, and Q. Guo, “Health-related quality of life in patients with spinal metastases treated with or without spinal surgery: a prospective, longitudinal study,” Cancer, vol. 116, no. 16, pp. 3875–3882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Guzman, S. Dubach-Schwizer, P. Heini et al., “Preoperative transarterial embolization of vertebral metastases,” European Spine Journal, vol. 14, no. 3, pp. 263–268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Wise, J. S. Fischgrund, H. N. Herkowitz, D. Montgomery, and L. T. Kurz, “Complication, survival rates, and risk factors of surgery for metastatic disease of the spine,” Spine, vol. 24, no. 18, pp. 1943–1951, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. R. B. North, V. R. LaRocca, J. Schwartz et al., “Surgical management of spinal metastases: analysis of prognostic factors during a 10-year experience,” Journal of Neurosurgery: Spine, vol. 2, no. 5, pp. 564–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. H. R. Dürr, B. Wegener, A. Krödel, P. E. Müller, V. Jansson, and H. J. Refior, “Multiple myeloma: surgery of the spine: retrospective analysis of 27 patients,” Spine, vol. 27, no. 3, pp. 320–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. D.-C. Cho and J.-K. Sung, “Palliative surgery for metastatic thoracic and lumbar tumors using posterolateral transpedicular approach with posterior instrumentation,” Surgical Neurology, vol. 71, no. 4, pp. 424–433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Hu, Q. Xia, J. Ji, and J. Miao, “One-stage combined posterior and anterior approaches for excising thoracolumbar and lumbar tumors: surgical and oncological outcomes,” Spine, vol. 35, no. 5, pp. 590–595, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. de Vries, A. C. M. Persoon, P. L. Jager et al., “Embolization therapy of bone metastases from epithelial thyroid carcinoma: effect on symptoms and serum thyroglobulin,” Thyroid, vol. 18, no. 12, pp. 1277–1284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. F. C. Tamburrelli, L. Proietti, L. Scaramuzzo, V. de Stefano, and C. A. Logroscino, “Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report,” European Spine Journal, vol. 21, no. 1, pp. S141–S145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Berenson, B. E. Hillner, R. A. Kyle et al., “American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma,” Journal of Clinical Oncology, vol. 20, no. 17, pp. 3719–3736, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. S. Rosen, D. Gordon, M. Kaminski et al., “Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial,” Cancer Journal, vol. 7, no. 5, pp. 377–387, 2001. View at Google Scholar · View at Scopus
  20. J. R. Berenson, L. S. Rosen, A. Howell et al., “Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases,” Cancer, vol. 91, no. 7, pp. 1191–1200, 2001. View at Google Scholar
  21. R. Mahtani, R. Khan, and M. Jahanzeb, “The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer,” Clinical Lung Cancer, vol. 12, no. 1, pp. 26–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Zarogoulidis, E. Boutsikou, P. Zarogoulidis et al., “The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis,” International Journal of Cancer, vol. 125, no. 7, pp. 1705–1709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Ory, M.-F. Heymann, A. Kamijo, F. Gouin, D. Heymann, and F. Redini, “Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice,” Cancer, vol. 104, no. 11, pp. 2522–2529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Hirsh, N. S. Tchekmedyian, L. S. Rosen, M. Zheng, and Y.-J. Hei, “Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications,” Clinical Lung Cancer, vol. 6, no. 3, pp. 170–174, 2004. View at Publisher · View at Google Scholar · View at Scopus